Abstract PR006: High melanoma-specific survival in patients with desmoplastic melanoma treated with single agent anti-PD-1 in SWOG S1512
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Desmoplastic melanoma is a rare subtype of cutaneous melanoma defined by extensive fibrosis (desmoplasia), and at the same time has pre-existing immune infiltrates and a high tumor mutational burden (TMB) resulting from exposure to ultraviolet (UV) light, which we hypothesized may result in high response rates to single-agent anti-programmed death protein 1 (PD-1) therapy. SWOG S1512 was a two-cohort phase 2 clinical trial: i) Cohort A included 28 eligible patients with surgically resectable desmoplastic melanoma who received a median of 3 infusions (range 1- 4) of neoadjuvant pembrolizumab 200 mg every 3 weeks, followed by surgical excision. pCR rate was 57% (95% CI: 37%-76%, p<0.001); none of the patients received adjuvant pembrolizumab (Kendra et al. ASCO 2022). ii) Cohort B included 27 eligible patients with unresectable desmoplastic melanoma who received a median of 15 infusions (range 1- 34) of pembrolizumab, 200 mg IV every 3 weeks. The objective response rate was 89% (95%, CI:71%-98%; Kendra et al. AACR 2023). At 3 years of follow-up, 13 patients have died (4 cohort A, 9 cohort B). Causes of death were: melanoma (1), cardiac (4), infections (2), stroke (1), pulmonary fibrosis (1), kidney failure (1), acute myelogenous leukemia (1), brain bleed related to a fall (1), and unknown (1). The combined 3-year melanoma-specific survival is 96% (n=55, 95%CI 87%-99%). In conclusion, patients with desmoplastic melanoma are exceptional responders to single-agent PD-1 blockade therapy, leading to long-term responses. Funding for this research was provided by NIH/NCI grants: U10CA180888 and U10CA180819 (SWOG); and in part by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USAFigure 1. Melanoma-specific survival in the combined cohorts A and B of S1512 (n = 55) at 3-year follow up. Death from other causes were treated as competing risks using the Fine-Gray model. Citation Format: Kari L kendra, shay l Bellasea, Zeynep Eroglu, Siwen Hu-Lieskovan, Katie M Campbell, William Carson III, David Wada, Jose A Plaza, Jeffery A Sosman, Gino In, Alexandra P Ikeguchi, John Hyngstrom, Andrew Brohl, Bartosz Chmielowski, Nikhil Khushalani, Joseph Markowitz, George Negrea, Samer Kasbari, Gary C Doolittle, Umang Swami, Toni Roberts, Marcus Monroe, Carlo Contreras, Edmidio Medina, Ignacio Baselga-Carretero, Cynthia R Gonzalez, Ivan Perez Garcilazo, Agustin Vega-Crespo, Jia Min Chen, nataly Nasar Al-Deen, Kenneth F Grossman, Vernon Sondak, elad sharon, Sapna P Patel, james moon, Michael C Wu, Antoni Ribas. High melanoma-specific survival in patients with desmoplastic melanoma treated with single agent anti-PD-1 in SWOG S1512 [abstract]. In: Proceedings of the AACR IO Conference: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2025 Feb 23-26; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(2 Suppl):Abstract nr PR006.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Abstract PR006: High melanoma-specific survival in patients with desmoplastic melanoma treated with single agent anti-PD-1 in SWOG S1512
- Date Crossref
- 23/02/2025
- Éditeur
- American Association for Cancer Research (AACR)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The Ohio State University Wexner Medical Center pays non établi dans la noticeÉtablissement de santé
-
Fred Hutch Cancer Center pays non établi dans la noticeOrganisation à but non lucratif
-
Moffitt Cancer Center pays non établi dans la noticeÉtablissement de santé
-
University of Utah pays non établi dans la noticeUniversité ou école supérieure
-
Huntsman Cancer Institute pays non établi dans la noticeÉtablissement de santé
-
University of California pays non établi dans la noticeUniversité ou école supérieure
-
Northwestern University pays non établi dans la noticeUniversité ou école supérieure
-
Midwestern University pays non établi dans la noticeUniversité ou école supérieure
-
University of Southern California pays non établi dans la noticeUniversité ou école supérieure
-
USC Norris Comprehensive Cancer Center pays non établi dans la noticeÉtablissement de santé
-
The University of Texas MD Anderson Cancer Center pays non établi dans la noticeÉtablissement de santé
-
UCLA Jonsson Comprehensive Cancer Center pays non établi dans la noticeÉtablissement de santé
The Ohio State University Wexner Medical Center, Fred Hutch Cancer Center et Moffitt Cancer Center, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.